QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads

被引:22
作者
Jawarkar, Rahul D. [1 ]
Sharma, Praveen [1 ]
Jain, Neetesh [1 ]
Gandhi, Ajaykumar [2 ]
Mukerjee, Nobendu [3 ]
Al-Mutairi, Aamal A. [4 ]
Zaki, Magdi E. A. [4 ]
Al-Hussain, Sami A. [4 ]
Samad, Abdul [5 ]
Masand, Vijay H. [6 ]
Ghosh, Arabinda [7 ]
Bakal, Ravindra L. [8 ]
机构
[1] Oriental Univ, Fac Pharm, Indore 453555, Madhya Pradesh, India
[2] Govt Coll Arts & Sci, Dept Chem, Aurangabad 431004, Maharashtra, India
[3] Ramakrishna Mission Vivekananda Centenary Coll, Dept Microbiol, Kolkata 700118, W Bengal, India
[4] Imam Mohammad Ibn Saud Islamic Univ, Fac Sci, Dept Chem, Riyadh 13318, Saudi Arabia
[5] Tishk Int Univ, Fac Pharm, Dept Pharmaceut Chem, Erbil 44001, Kurdistan Regio, Iraq
[6] Vidyabharati Mahavidyalalya, Dept Chem, Camp Rd, Amravati 444602, Maharashtra, India
[7] Gauhati Univ, Dept Bot, Microbiol Div, Gauhati 781014, Assam, India
[8] Dr Rajendra Gode Inst Pharm, Dept Med Chem, Univ Mardi Rd, Amravati 444603, Maharashtra, India
来源
MOLECULES | 2022年 / 27卷 / 15期
关键词
ALK tyrosine kinase inhibitors; QSAR; anticancer; molecular docking; MD simulation; MMGBSA; DIFFERENT VALIDATION CRITERIA; REAL EXTERNAL PREDICTIVITY; PYMOL PLUGIN; CRIZOTINIB; LYMPHOMA; RECEPTOR; GENE; CHEMOTHERAPY; ACTIVATION; CERITINIB;
D O I
10.3390/molecules27154951
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
ALK tyrosine kinase ALK TK is an important target in the development of anticancer drugs. In the present work, we have performed a QSAR analysis on a dataset of 224 molecules in order to quickly predict anticancer activity on query compounds. Double cross validation assigns an upward plunge to the genetic algorithm-multi linear regression (GA-MLR) based on robust univariate and multivariate QSAR models with high statistical performance reflected in various parameters like, fitting parameters; R-2 = 0.69-0.87, F = 403.46-292.11, etc., internal validation parameters; Q(LOO)(2) = 0.69-0.86, Q(LMO)(2) = 0.69-0.86, CCCcv = 0.82-0.93, etc., or external validation parameters Q(F1)(2) = 0.64-0.82, Q(F2)(2) = 0.63-0.82, Q(F3)(2) = 0.65-0.81, R-ext(2) = 0.65-0.83 including RMSEtr < RMSEcv. The present QSAR evaluation successfully identified certain distinct structural features responsible for ALK TK inhibitory potency, such as planar Nitrogen within four bonds from the Nitrogen atom, Fluorine atom within five bonds beside the non-ring Oxygen atom, lipophilic atoms within two bonds from the ring Carbon atoms. Molecular docking, MD simulation, and MMGBSA computation results are in consensus with and complementary to the QSAR evaluations. As a result, the current study assists medicinal chemists in prioritizing compounds for experimental detection of anticancer activity, as well as their optimization towards more potent ALK tyrosine kinase inhibitor.
引用
收藏
页数:27
相关论文
共 44 条
[11]  
Gramatica P., 2020, Int. J. Quant. Struct. -Prop. Relatsh, V5, P61, DOI [10.4018/ijqspr.20200701.oa1, DOI 10.4018/IJQSPR.20200701.OA1, 10.4018/IJQSPR.20200701. oa1]
[12]   QSARINS: A new software for the development, analysis, and validation of QSAR MLR models [J].
Gramatica, Paola ;
Chirico, Nicola ;
Papa, Ester ;
Cassani, Stefano ;
Kovarich, Simona .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2013, 34 (24) :2121-2132
[13]  
Gramatica Paola, 2013, Methods Mol Biol, V930, P499, DOI 10.1007/978-1-62703-059-5_21
[14]   The role of the ALK receptor in cancer biology [J].
Hallberg, B. ;
Palmer, R. H. .
ANNALS OF ONCOLOGY, 2016, 27 :4-15
[15]  
Holla VR, 2017, CSH MOL CASE STUD, V3, DOI 10.1101/mcs.a001115
[16]   Why QSAR Fails: An Empirical Evaluation Using Conventional Computational Approach [J].
Huang, Jianping ;
Fan, Xiaohui .
MOLECULAR PHARMACEUTICS, 2011, 8 (02) :600-608
[17]   Comprehensive assessment of flexible-ligand docking algorithms: current effectiveness and challenges [J].
Huang, Sheng-You .
BRIEFINGS IN BIOINFORMATICS, 2018, 19 (05) :982-994
[18]   Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system [J].
Iwahara, T ;
Fujimoto, J ;
Wen, DZ ;
Cupples, R ;
Bucay, N ;
Arakawa, T ;
Mori, S ;
Ratzkin, B ;
Yamamoto, T .
ONCOGENE, 1997, 14 (04) :439-449
[19]   Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations [J].
Johnson, Ted W. ;
Richardson, Paul F. ;
Bailey, Simon ;
Brooun, Alexei ;
Burke, Benjamin J. ;
Collins, Michael R. ;
Cui, J. Jean ;
Deal, Judith G. ;
Deng, Ya-Li ;
Dinh, Dac ;
Engstrom, Lars D. ;
He, Mingying ;
Hoffman, Jacqui ;
Hoffman, Robert L. ;
Huang, Qinhua ;
Kania, Robert S. ;
Kath, John C. ;
Lam, Hieu ;
Lam, Justine L. ;
Le, Phuong T. ;
Lingardo, Laura ;
Liu, Wei ;
McTigue, Michele ;
Palmer, Cynthia L. ;
Sach, Neal W. ;
Smeal, Tod ;
Smith, Graham L. ;
Stewart, Albert E. ;
Timofeevski, Sergei ;
Zhu, Huichun ;
Zhu, Jinjiang ;
Zou, Helen Y. ;
Edwards, Martin P. .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) :4720-4744
[20]   Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids [J].
Jorgensen, WL ;
Maxwell, DS ;
TiradoRives, J .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1996, 118 (45) :11225-11236